The experimental alzheimer drug phenserine: Preclinical pharmacokinetics and pharmacodynamics

Acta Neurologica Scandinavica, Supplement

Volumn 102, Issue 176, 2000, Pages 74-84

  Greig, N H ^a   De Micheli, E ^a   Holloway, H W ^a   Yu, Q S ^a   Utsuki, T ^a   Perry, T A ^a   Ingram, D K ^a   Deutsch, J ^a   Lahiri, D ^b   Soncrant, T T ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cure Inc   (United States)

Author keywords

Acetylcholine; Acetylcholinesteras e; Alzheimer's disease; Anticholinesterases; Butyrylcholinesterase; Cholinomimetics; In vivo microdialysis

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; EPTASTIGMINE; HEPTYLSTIGMINE TARTRATE; PHENSERINE; PHYSOSTIGMINE; SYNAPTON; TACRINE; DRUG DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MICRODIALYSIS; NONHUMAN; RAT; ANIMAL; BRAIN; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; FISCHER 344 RAT; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHYSIOLOGY;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; DISEASE MODELS, ANIMAL; HALF-LIFE; INFUSIONS, INTRAVENOUS; MALE; PHYSOSTIGMINE; RATS; RATS, INBRED F344; TACRINE;

EID: 0034574284     PISSN: 00651427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Cholinesterase inhibitors do more than inhibit cholinesterase
2. Cholinesterase inhibitors as therapy in Alzheimer's disease: Benefit to risk considerations in clinical application
3. Alzheimer's disease: A central role of β-amyloid
4. Processing of β-amyloid precursor protein and its regulation in Alzheimer's disease
5. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
6. Cell loss from the nucleus basalis of Meynert in Alzheimer's disease
7. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
8. Neuropathological basis of Alzheimer's disease, implications for treatment
9. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia
10. Human memory and the cholinergic system: A relationship to aging?
11. Aging and dementia: Insights from the study of anticholinergic drugs
12. Cholinergic systems and related neuropathological predilection patterns in Alzheimer Disease
13. Calcium regulates processing of the Alzheimer's amyloid protein precursor in a protein kinase C-independent manner
14. Regulation of APP processing by first messengers
15. The cholinergic hypothesis of geriatric memory dysfunction
16. Mechanism of cholinesterase inhibition in senile dementia of the Alzheimer-type: Clinical, pharmacological and therapeutic aspects
17. The second generation of cholinesterase inhibitors: Clinical and pharmacological effects
18. Donepezil use in Alzheimer disease
19. Treatment of Alzheimer's disease by continuous intravenous infusion of physostigmine
20. Performance of aged rats in a 14-unit T-maze is improved following chronic treatment with phenserine, a novel long-acting anticholi-nesterase
21. Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor
22. Phenserine, a novel anti-cholinesterase related to physostigmine: Total synthesis, and biological properties
23. Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterase
24. A new and rapid colorimetric determination of acetylcholinesterase activity
25. An alogrithm for least squares estimation of nonlinear parameters
26. A long-lasting cholinesterase inhibitor affecting neural and behavioral processes
27. Preclinical and clinical studies with galanthamine
28. Comparison of butyrylcholi-nesterase and acetylcholinesterase
29. Systematic regional differences in the cholinergic inervation of the primate cerebral cortex; distribution of enzyme activities and some behavioral implications
30. CP-118,954: A potent and selective AChE inhibitor. The importance of selective AChE inhibition in vivo
31. Pharmacokinetics and pharma-codynamics of physostigmine in the rat after intravenous administration
32. Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration
33. Drug entry to the brain and its pharmacologic manipulation
34. Heptylphysostigmine: A potent inhibitor of acetylcholines-terase with long duration of action
35. Kinetics of human erythrocyte acetylcholines-terase inhibition by a novel derivative of physostigmine: Phenserine
36. The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairments of rats in a 14-unit T-maze
37. Raised glucose levels enhance scopolamine-induced acetylcholine overflow of the hippocampus: An in vivo microdialysis study in the rat
38. Cholinesterase inhibitor effects on extracellular acetylcholine in the rat striatum
39. Effects of morphine on release of acetylcholine in the rat striatum: An in vivo microdialysis study
40. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex
41. Determination of basal acetylcholine release in vivo by rat brain dialysis with a U-shaped cannula: Effect of SM-10,888, a putative therapeutic drug for Alzheimer's disease
42. Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after cholinesterase inhibition
43. Effect of E2020 on the extracellular level of acetylcholine in the rat cerebral cortex measured by microdialysis without addition of cholinesterase inhibitor
44. Inhibition of acetylcholinesterase by new physostigmine derivatives
45. Cholinomimetic replacement of cholinergic function in Alzheimer's disease
46. Phenserine: A physostigmine derivative that is a long-acting inhibitor of acetylcholinesterase and demonstrates a wide dose-range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze
47. Physostigmine improves water maze performance following nucleus basalis magnocellularis lesion in rats
48. Reversal by tetrahy-droaminoacridine of scopolamine-induced memory and performance deficits in rats
49. Pharmacological modulation of Alzheimer's β-amyloid precrusor protein levels in the CSF of rats with forebrain cholinergic system lesions
50. Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease
51. Drug therapy: Drug disposition in old age
52. Aging and drug disposition: An update